Site Editors
Shaji K. Kumar, MD
Prashant Kapoor, MD, FACP
Shaji K. Kumar, MD
Prashant Kapoor, MD, FACP
Posted: Friday, July 7, 2023
A subset of results from the phase II MagnetisMM-3 trial, which included patients naive to B-cell maturation agent–directed therapies, was presented at the European Hematology Association (EHA) 2023 Hybrid Congress (Abstract S196). The presentation addressed the efficacy of elranatamab in patients with relapsed or refractory multiple myeloma after 1 year of follow-up as well as the switch to dosing every 2 weeks. The work was presented by Mohamad Mohty, MD, PhD, of Sorbonne University, Paris, and colleagues.
“These results support the continued development of elranatamab both as a monotherapy and in combination with standard or novel therapies for patients with multiple myeloma,” the investigators noted.
A total of 123 eligible patients had refractory myeloma to at least one proteasome inhibitor, one immunomodulatory drug, and one anti-CD38 antibody. These patients received therapy with elranatamab in a 28-day cycle, with step-up doses of 12 mg, 32 mg, and 72 mg in 4-day intervals leading to day 8.
The authors reported median progression-free and overall survival rates at 12 months of 57.1% and 62.0%, respectively. The objective response rate was 61%, with 31.7% of patients exhibiting a complete response. A partial response to elranatamab was observed in 29.3% of patients. Furthermore, the measurable residual disease (MRD) negativity threshold was achieved by 92% of patients. The group noted that the median duration of response had not been reached, but the median duration of response at 12 months was 74.1%.
Of note, when dosing was switched to every 2 weeks, 80.4% of patients maintained or improved their response. The safety report found the most common grade 3 or 4 treatment-emergent adverse events to be hematologic. Nonhematologic events that occurred in more than 5% of patients included COVID-19, hypokalemia, pneumonia, sepsis, and hypertension. However, after switching to biweekly dosing, the researchers observed a decrease of 10% in grade 3 or 4 adverse events.
Disclosure: Disclosure information for the study authors was not provided.
JNCCN Spotlights
